Tramadol
Tramadol hydrochloride
Brand names:Ultram, ConZip, Ryzolt
A Schedule IV opioid analgesic with dual mu-opioid receptor agonism and SNRI activity. Tramadol's tactical role is limited by unpredictable pharmacogenomic response (CYP2D6 variability), serotonin syndrome risk in operators on SSRIs, and seizure threshold lowering in TBI populations. The TCCC analgesic ladder (acetaminophen plus meloxicam for mild, fentanyl for moderate to severe, ketamine for refractory) provides better predictability.
Pharmacology and Actions
Tramadol has a dual mechanism: it is a weak mu-opioid receptor agonist (the parent compound has weak affinity; the M1 metabolite, formed via CYP2D6, has stronger affinity), and it inhibits reuptake of serotonin and norepinephrine. The SNRI activity contributes to analgesia and also drives the seizure and serotonin syndrome risk. Tramadol's analgesic effect depends on CYP2D6 conversion to its active metabolite, with significant pharmacogenomic variability.
Indications
- Moderate to moderately severe pain (acute and chronic)
- Pain not controlled by acetaminophen or NSAIDs
- Step before stronger opioid analgesics
- Operational analgesia for moderate musculoskeletal pain when NSAIDs contraindicated
Absolute Contraindications
- Known hypersensitivity to tramadol or opioids
- Severe respiratory depression or acute asthma
- GI obstruction (including paralytic ileus)
- Concurrent MAOI use or within 14 days of MAOI discontinuation
- Severe hepatic impairment (extended-release formulations)
- Children under 12 years; post-tonsillectomy or post-adenoidectomy contraindicated under 18 years
Precautions and Side Effects
Common: nausea and vomiting (very common, especially at initiation - dose titration helps), constipation, dizziness, somnolence, sweating. Less respiratory depression than equianalgesic doses of morphine, but real. Seizure risk (independent of dose for predisposed patients). Serotonin syndrome (especially with concurrent serotonergic agents). Physical dependence and withdrawal with chronic use. Drug interactions: serotonergic drugs (SSRIs, SNRIs, TCAs, triptans, MAOIs, linezolid, methylene blue) cause serotonin syndrome risk; CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine, bupropion) reduce M1 conversion and analgesia; CYP3A4 inducers (rifampin, carbamazepine) reduce levels; other opioids and CNS depressants cause additive respiratory depression; alcohol significantly increases CNS depression. Half-life 5 to 7 hours (parent), 7 to 8 hours (active metabolite); prolonged in renal and hepatic impairment. Pregnancy Category C (avoid; neonatal withdrawal possible). Passes into breast milk; neonatal CNS depression reported. Elderly: increased sedation and falls risk. Renal impairment: extend dosing interval. Hepatic impairment: avoid extended-release; reduce immediate-release dose. About 5 to 10 percent of patients are CYP2D6 poor metabolizers (minimal analgesia); 1 to 7 percent are ultrarapid metabolizers (opioid toxicity risk).
Adult Dosing
Pediatric Dosing
Not recommended under 12 years. Adolescents 12 to 17 years: caution due to CYP2D6 variability; not recommended for post-surgical pain after tonsillectomy or adenoidectomy.
Pharmacokinetics
Peak Effect: 2 to 3 hours.
Duration: 6 hours (immediate-release); 24 hours (extended-release).
Storage and Handling
Schedule IV controlled substance - secured storage required, documented chain of custody, log all administrations and waste. Room temperature, protect from light.
Reconstitution:
Oral formulation only in the United States.
TCCC and TECC Role
Tramadol is not in the TCCC core formulary. TCCC 2026 retains fentanyl, ketamine, and meloxicam plus acetaminophen as the analgesic tools. Tramadol's tactical role is limited - it sits in a middle ground where the operational profile is questionable. The seizure risk (especially in TBI patients), serotonin syndrome risk in operators on SSRIs (common in the population), and unpredictable pharmacogenomic response make it a less reliable tactical analgesic than alternatives. Mission impact is substantial: sedation, nausea, and dizziness are all common.
Tramadol occupies an unfortunate niche. It is Schedule IV (lighter regulatory burden than Schedule II opioids), which makes it attractive to prescribers, but its operational profile is full of pitfalls. The CYP2D6 variability means you cannot predict who will get good analgesia and who will get none. The serotonin syndrome risk in operators on SSRIs (a substantial fraction of military and LE populations) is real and dangerous. The seizure risk in any patient with TBI history - a population that overlaps with tactical operators - makes this a deliberate choice rather than a default. For most operational pain scenarios, the TCCC analgesic ladder provides better predictability and safety.
Treating tramadol as a non-opioid because it is Schedule IV and feels less serious than morphine or fentanyl. It is an opioid (and a serotonergic agent), and respiratory depression, dependence, withdrawal, and overdose all happen. The other mistake is co-prescribing with SSRIs without recognizing serotonin syndrome risk - operators on sertraline, fluoxetine, or escitalopram should not be given tramadol without considering this. The third mistake is using tramadol in TBI patients; the seizure threshold lowering effect is real and dangerous in this population.
This drug profile is provided as educational reference material for trained medical providers. It is not medical advice, not a substitute for formal training, and not a substitute for current published guidelines or medical direction.
Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances are subject to additional handling, accountability, and documentation requirements per DEA and state law. Always verify dosing, indications, contraindications, and route of administration against current published guidelines and your local protocols before administration.
If this content is being viewed during a medical emergency, call 911 immediately and follow the direction of your local emergency dispatch and medical control. Do not use this reference as a substitute for emergency medical services.
Drug information evolves. Last reviewed dates and source citations are provided for each entry. Confirm currency against the cited source before clinical use.
Penn Tactical Solutions publishes this reference for educational purposes. PTS does not provide medical direction and does not assume responsibility for clinical decisions made in the field. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Educational reference for trained medical providers. Not medical advice. Not a substitute for formal training, current published guidelines, or medical direction. Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances require additional storage, accountability, and documentation per DEA and state law.
In a medical emergency, call 911. This reference is not a substitute for emergency medical services.
Verify dosing, indications, and contraindications against current published guidelines and your local protocols before administration. Confirm content currency against the source citation. Penn Tactical Solutions does not provide medical direction. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Tramadol
Schedule IV| IV/IO | None (not approved IV in the United States; available IV in some countries). (None) |
| IM | None (not standard in US). (None) |
| IN | None (None) |
| PO | Immediate-release: 50 to 100 mg PO every 4 to 6 hours as needed. Initiate with 25 mg daily and titrate to reduce nausea. Maximum 400 mg per 24 hours. Extended-release: 100 mg PO daily, titrate weekly; maximum 300 mg per 24 hours. (1 hour) |